Lexette
(halobetasol)Small molecule
Lexette is one of 29 small molecule programs targeting Psoriasis. It is currently in development.
1
Indications
1
Total Trials
0
Active Trials
28
Competitors
5
FDA Applications
NDA/BLA/ANDA regulatory filings
7
Patents
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
605 competitors in Psoriasis
#DrugCompanyPhaseTrials
1Cosentyx
NovartisPreclinical
Taltz
Eli LillyPreclinical
Bimzelx
UCBPreclinical
Humira
CCelltrion
Preclinical
Ilumya
Sun Pharmaceutical Industries, Inc.Preclinical
Raptiva
RochePreclinical
Remicade
OOrganon and Co
Preclinical
Siliq
BBausch Health Americas, Inc.
Preclinical
Victoza
Novo NordiskPreclinical
Lovenox
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Dec 17, 1990
ULTRAVATE
NDA NDA019968
Dec 27, 1990
ULTRAVATE
NDA NDA019967
Nov 6, 2015
ULTRAVATE
NDA NDA208183
May 24, 2018
LEXETTE
NDA NDA210566
Nov 6, 2018
BRYHALI
NDA NDA209355
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for halobetasol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- BBiomed Industries, Inc.